Skip to main content

Table 9 Valanafusp alpha anti-drug antibody (ADA) titers

From: Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

  Week Patient number
202 203 204 205 206 207 211 213 214 215 216
ADAa titer 0 0 0 0 0 450 36,450 0 36,450 0 1,350 1,350
2 0 0 0 0 450 109,350 0 4,050 0 1,350 4,050
4 0 4,050 0 0 450 328,050 1,350 12,150 4,050 150 4,050
8 50 0 0 150 1,350 328,050 0 109,350 12,150 150 1,350
12 0 0 0 50 1,350 328,050 450 36,450 36,450 150 12,150
16 150 0 0 0 1,350 109,350 1,350 36,450 36,450 150 4,050
20 150 0 0 1,350 450 109,350 1,350 36,450 109,350 12,150 12,150
26 150 0 0 50 4,050 109,350 12,150 36,450 328,050 4,050 36,450
39 50 150 0 50 50 109,350 36,450 36,450 328,050 4,050 12,150
52 50 450 50 450 1,350 109,350 12,150 35,450 328,050 4,050 36,450
ERTb   8 2 5 1 2 3 0 4 0 4 1
IRRc   1 0 0 0 0 1 1 1 6 0 0
  1. aADA titer is dilution of serum giving ELISA response above background
  2. bERT is the number of years on laronidase treatment prior to enrollment
  3. cIRR is the number of infusion related reactions over 52-week study